• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cn-15 * adverse effects of bevacizumab in brain tumor patients
CONCLUSION: The range of toxicities was similar to other reports. Interestingly, hypertension was the most common adverse effect and was often not treated. The high incidence of lymphocytopenia may have implications for combination with immunotherapies. These findings underscore the need to develop predictive models to identify patients at high risk for serious treatment-related toxicities.
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Pawar, T., Ladha, H., Mandel, J., Gilbert, M., O'Brien, B., Hamza, M., Armstrong, T. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research

1497p * lessons from the past: long-term safety and efficacy outcomes of a prematurely terminated, randomized phase iii trial of precautionary versus hemoglobin-based erythropoietin administration for chemotherapy-associated anemia in patients with solid tumors
Conclusions: Prophylactic administration of ESA for CIA in patients with solid tumors was associated with increased incidence of a composite of thrombosis-related adverse events, especially in patients receiving adjuvant treatment, but did not have a detrimental impact on relapse/progression and survival rates.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Mountzios, G., Aravantinos, G., Kouvatseas, G., Karina, M., Samantas, E., Papakostas, P., Skarlos, D., Galani, E., Kalofonos, H., Makatsoris, T., Bafaloukos, D., Pectasides, D. G., Fountzilas, G. Tags: supportive care Source Type: research

432p * patterns and efficacy of bevacizumab use across treatment lines in glioblastoma
Conclusions: Our results show bevacizumab treatment may be more efficient after a recurrence than when used in the beginning of treatment and are in line with reported registration trials data.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Azam, M. B., Rho, Y. S., Mamo, A., Sahebjam, S., Muanza, T., Guiot, M., Al-Shami, J., Sharma, R., Kavan, P. Tags: CNS tumours Source Type: research

Venous thromboembolism in children with acute lymphoblastic leukemia
Abstract Venous thromboembolism (VTE) occurs in 0.95–36 % of children with acute lymphoblastic leukemia almost exclusively during chemotherapy. It is most commonly associated with concurrent l-asparaginase and steroid therapy, central venous line use, and inherited thrombophilia. Clinical manifestations regarding the location of VTE include central nervous system thrombosis (sinus venous thrombosis, cerebral infarct/stroke), upper-/lower-limb deep venous thrombosis, pulmonary embolism, and right atrial/intracardiac and superficial venous thrombosis and can be both symptomatic and asymptomatic. The majority of ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research

Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer Health Services and Outcomes
Conclusion Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed.
Source: Journal of Clinical Oncology - September 27, 2013 Category: Cancer & Oncology Authors: Hershman, Wright, Lim, Buono, Tsai, Neugut Tags: Quality of Care, Quality of Care Health Services and Outcomes Source Type: research

Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer.
CONCLUSION: Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed. PMID: 24002522 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - September 3, 2013 Category: Cancer & Oncology Authors: Hershman DL, Wright JD, Lim E, Buono DL, Tsai WY, Neugut AI Tags: J Clin Oncol Source Type: research

Stroke with intracranial stenosis is associated with increased platelet activation in sickle cell anemia
ConclusionStroke with intracranial stenosis is associated with increased platelet activation in sickle cell anemia, and further investigation is needed on the role of anti‐platelet agents in this high‐risk population. Pediatr Blood Cancer © 2013 Wiley Periodicals, Inc.
Source: Pediatric Blood and Cancer - March 18, 2013 Category: Cancer & Oncology Authors: Suvankar Majumdar, Samantha Webb, Erin Norcross, Venkat Mannam, Naveed Ahmad, Seth Lirette, Rathi Iyer Tags: Research Article Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13